Tango Therapeutics(TNGX) - 2024 Q1 - Quarterly Results

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights – Dose expansion initiated in TNG908 phase 1/2 clinical trial – – Dose expansion expected to initiate in TNG462 phase 1/2 clinical trial in 2Q 2024 – – Clinical data expected in 2H 2024 from PRMT5 program – – Dose escalation ongoing in TNG260 and TNG348 clinical-stage precision oncology programs – – Strong cash position of $344 million as of March 31, 2024; cash runway into late 2026 expected to fund all clinica ...